Table 1

Demographic, clinical and MRI characteristics of HC and patients with MS

Demographic and clinical variablesHC (n=175)MS (n=489)p Value
Females, n (%)123 (70.7)345 (70.6)0.247
Age in years, mean (SD)46.4 (13.7)47.3 (10.9)0.374
Age at onset, mean (SD)32.3 (9.9)
Expanded Disability Status Scale, median (IQR)3.0 (8.5)
Disease duration in years, mean (SD)15.1 (10.5)
Race, n (%)
 Caucasian147 (84)449 (91.8)0.424
 African–American16 (9.1)18 (3.7)
 Other12 (6.9)22 (4.5)
Disease-modifying therapy, n (%)
 No therapy132 (26.7)
 Interferon β-1a intramuscular118 (24.1)
 Glatiramer acetate98 (20)
 Natalizumab73 (14.9)
 Interferon β-1a subcutaneous40 (7.9)
 Combination therapy28 (6.7)
MRI variables, mean (SD)
 T2-LN2.5 (6.7)28.9 (19.7)<0.0001
 T2-LV0.3 (1.1)13.9 (15.8)<0.0001
 T1-LN11.3 (11.7)
 T1-LV3.2 (6.1)
 NBPV1523.9 (81.4)1468.6 (92.9)<0.0001
 NGMV768 (52.1)731 (65.5)<0.0001
 NWMV755.9 (67)737.6 (66.4)0.0001
 NLVV33.6 (13.7)49.8 (22.3)<0.0001
  • Differences between groups were analysed by the χ2 test and analysis of variance. MRI differences between groups were analysed using the analysis of covariance, adjusted for age and sex. MRI volumes are expressed in millilitres.

  • BMI, body mass index; HC, healthy controls; LN, lesion number; LV, lesion volume; MS, multiple sclerosis; NBPV, normalised brain parenchymal volume; NGMV, normalised grey matter volume; NLVV, normalised lateral ventricle volume; NWMV, normalised white matter volume.